相关实验视频

Updated: Jul 5, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

在冠状动脉疾病中,CDKN2B-AS1可能充当miR-92a-3p海绵

Fei Xie¹, Dan Wang¹, Ming Cheng²

¹Department of Cardiac Surgery, The Second Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China.

Minerva cardiology and angiology

|January 17, 2024

概括

长非编码RNAs (lncRNAs) 和微RNAs (miRNAs) 影响冠状动脉疾病 (CAD). 这项研究确定CDKN2B-AS1为hsa-miR-92a-3p的海绵,可能调节CAD进展.

科学领域:

分子生物学分子生物学
遗传学遗传学是一个
心血管研究研究心血管研究

背景情况:

长非编码RNAs (lncRNAs) 和microRNAs (miRNAs) 在冠状动脉疾病 (CAD) 的发病和进展中发挥着关键作用.
在lncRNA-miRNA网络中的复杂的调节相互作用对于理解CAD至关重要.
探索这些网络对于在CAD中识别新的治疗点至关重要.

研究的目的:

研究冠状动脉疾病 (CAD) 中的lncRNA-miRNA-基因调节网络.
为了确定参与CAD病变发生的关键调节分子.
阐明潜在的新型机制,以CAD为基础.

主要方法:

利用CAD患者和对照组的基因表达数据 (GSE98583) 来识别使用Limma包的差异表达基因 (DEG).
进行了功能丰富分析 (DAVID) 并从数据库 (HMDD,miRTarBase,LncRNADisease,starBase) 中检索了lncRNA-miRNA和miRNA-DEG的关联.
构建了CAD相关的lncRNA-miRNA-DEG网络,并使用双化酶试验验验证了关键相互作用.

主要成果:

在CAD和对照样本之间确定了534个DEG (243个上调,291个下调),富含重要的生物过程和途径.
确定了几个与CAD相关的针对DEGs的miRNAs,其中hsa-miR-92a-3p调节了大多数DEGs.
证实CDKN2B-AS1通过双化酶测定,通过双化酶测定,专门调节hsa-miR-92a-3p,这是CAD中的关键miRNA.

结论:

CDKN2B-AS1作为hsa-miR-92a-3p的分子海绵,从而调节下游在CAD中差异性表达的基因.
CDKN2B-AS1/hsa-miR-92a-3p/GATA2轴代表了冠状动脉疾病发展中的潜在新型调节机制.

更多相关视频

Visualization of Cell Cycle Variations and Determination of Nucleation in Postnatal Cardiomyocytes

Visualization of Cell Cycle Variations and Determination of Nucleation in Postnatal Cardiomyocytes

Published on: February 24, 2017

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...